Other
Toripalimab
0
Pipeline Programs↗
12
Active Trials↗
1
Companies Involved↗
Toripalimab is an early-stage landscape with 0 programs across 1 company. The most active players are Eucure (Beijing) Biopharma Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
24
clinical trials
Unknown status7 · 29%
Recruiting7 · 29%
Completed4 · 17%
Not yet recruiting4 · 17%
Active, not recruiting1 · 4%
Withdrawn1 · 4%
Clinical Trials
Trial Activity
24 trials
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06221670·51 enrolled
Toripalimab Combined With SBRT for NSCLC
Active, not recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06293690·40 enrolled
Study of Sacituzumab Govitecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07438600·38 enrolled
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
Completed·—·Phase 2·NCT04044313·36 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)